Taken together, there is evidence regarding components of ACE2-Ang(1-7)-Mas axis involvement in CAD devolvement and progression; however, to further elucidate the therapeutic potential of modulation of this axis will require utilization of more selective tools to separate the upstream RAS effects provided by ACE inhibitors or AT1 blockers in general CAD therapy. The gene discussed is AGTR1; the disease is coronary artery disorder.